Study reveals statins are associated with a reduced risk of Alzheimer's disease, but the reduction of risk varied by race, ethnicity and statin type.
A clinical trial is being conducted to assess the effectiveness of a cholesterol lowering drug in the treatment of Parkinson's disease.
Researchers report statins could potentially reduce cardiovascular risks in people with Friedreich's ataxia.
The common statin drug Simvastatin reduces brain atrophy and slows the progression of secondary progressive multiple sclerosis (SPMS). The effects appear to be independent of the drug's cholesterol-lowering effects.